李韋宗
職稱 副教授
姓名 李韋宗
電子郵件
Phone: (03) 4227151 ext. 65904
網站 https://sites.google.com/site/leeinorganiclab/
專業領域 無機化學
研究興趣 配位化學 , 有機金屬, 無機反應機制
個人著作參考網址 "https://sites.google.com/site/leeinorganiclab/Publications"
個人研究計畫參考網址
學歷
學校名稱 系所 學位 期間
美國愛荷華大學 化學系 博士 2005.08 ~ 2011.12
國立清華大學 化學系 碩士 1999.09 ~ 2001.06
高雄醫學院 化學系 學士 1995.09 ~ 1999.06
經歷
服務機關名稱 職務 期間
美國芝加哥洛約拉大學 副教授 2020.03 ~ 2023.07
美國芝加哥洛約拉大學 助理教授 2014.08 ~ 2020.03
美國印第安那大學 博士後研究員 2013.09 ~ 2014.07
美國新墨西哥州立大學 博士後研究員 2012.01 ~ 2013.08
個人研究

Coordination Chemistry and Bioinorganic Chemistry

We are interested in the synthesis and spectroscopic studies of transition metal complexes. Particularly, by proper ligand design, we are able to control the coordination geometry of the reactive molecules which could in turn alter the redox properties on metal ions, and help us understand the catalytic mechanisms.

In order to understand the structure and function of active site of metalloenzymes, we will prepare the model compounds and characterize them by using electrochemistry, kinetic, and spectroscopic studies.

1
A dinuclear complex with shortest Fe(II)-Fe(II) bond
這是一張圖片
Fe2S2 model complex


 

Inorganic Catalysis and Renewable Energy

We will focus on design of well-defined complexes as homogeneous catalysts with bi- and tri-dentate ligand and earth-abundant, first-row transition metals. The application will also include the activation of small molecules like dinitrogen, dioxygen, carbon dioxide, and hydrocarbons such as methane. In addition, we will also develop the inorganic/organometallic molecules for the conversion and storage of renewable energy.

3
Hemilabile ligand supported Fe(II) complex as a pre-catalyst for hydrosilylation
5
Well-defined Ni(II) complex for H2 production


 

Medicinal Inorganic Chemistry

We investigate the field of medicinal inorganic chemistry such as metal-based therapeutic with possible applications in the treatment of cancer and Type II Diabetes. The research will center around developments of inorganic/organometallic compounds in relation to their activity and understanding the mechanisms of action.

5
Ruthenium-based anticancer agent
6
Simple vanadium-based agent for type II diabetes treatment